https://www.selleckchem.com/pr....oducts/nocodazole.ht
There was no significant change in peak time. The peak AST5902 concentration and AUC0-∞ were 27.4% and 71.4%, respectively, of that of alflutinib. None of the subjects experienced serious AEs, and both fasting and high-fat meal administration were safe. There was no statistically significant difference between groups in AEs (P = 0.102, RR = 1.4 or adverse reactions (P = 0.180, RR = 1.3. The effects of food may not need to be considered for the clinical use of alflutinib. No serious AEs occurred, and drug administration was safe a
Like
Comment
Share
